Traceable Bioinspired Nanoparticle for the Treatment of Metastatic Breast Cancer via NIR‐Trigged Intracellular Delivery of Methylene Blue and Cisplatin

Zhai, Yi­hui; Wei, Ran; Su, Jinghan; Lang, Tianqun; Meng, Jiao; Wang, Guanru; Zhang, Pengcheng; Li, Yaping

doi:10.1002/adma.201802378

Cited by 75 publications

(71 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To demonstrate the potential of PD‐L1 silencing for the treatment of metastatic cancer, the antitumor effect of BMS‐202 NPs was further studied using a lung metastatic 4T1 tumor model ( Figure a). The initial step was to intravenously inject 4T1 cells (1 × 10 4 ) into BALB/c mice, which were expected to grow and form lung metastases . The tumor‐bearing mice were then divided into five groups ( n = 5): 1) PBS (i.v.…”

Section: Methodsmentioning

confidence: 99%

Immune Checkpoint Blockade Mediated by a Small‐Molecule Nanoinhibitor Targeting the PD‐1/PD‐L1 Pathway Synergizes with Photodynamic Therapy to Elicit Antitumor Immunity and Antimetastatic Effects on Breast Cancer

Zhang

Zhu

et al. 2019

Small

136

114

View full text Add to dashboard Cite

In recent years, stimulating the host immune system to create a promising antitumor immune therapy has been demonstrated to control metastatic tumor growth. [1] Research enthusiasm has been fueled by recent clinical successes in which antibodies were used to block immune inhibitory pathways, specifically the axis between programmed cell death protein 1 (PD-1) and its ligand 1 (PD-L1). [2] However, therapeutic antibodies exhibit several disadvantages, such as limited tissue and tumor penetration, very long half-life time, immunogenicity, and costly production. Moreover, the current PD-1/PD-L1 axis-directed monoclonal antibodies lead to a tumor response only in a fraction of cases and tumor types. [3] Therefore, the application of alternative, nonantibody-based agents to inhibit PD-1/ PD-L1 axis is currently a new goal within the field. [4] The development of organic smallmole cule inhibitors is expected to introduce a number of advantages in the field of PD-1/PD-L1 immune checkpoint Targeting programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) immunologic checkpoint blockade with monoclonal antibodies has achieved recent clinical success in antitumor therapy. However, therapeutic antibodies exhibit several issues such as limited tumor penetration, immunogenicity, and costly production. Here, Bristol-Myers Squibb nanoparticles (NPs) are prepared using a reprecipitation method. The NPs have advantages including passive targeting, hydrophilic and nontoxic features, and a 100% drug loading rate. BMS-202 is a small-molecule inhibitor of the PD-1/PD-L1 interaction that is developed by BMS. Transfer of BMS-202 NPs to 4T1 tumor-bearing mice results in markedly slower tumor growth to the same degree as treatment with anti-PD-L1 monoclonal antibody (α-PD-L1). Consistently, the combination of Ce6 NPs with BMS-202 NPs or α-PD-L1 in parallel shows more efficacious antitumor and antimetastatic effects, accompanied by enhanced dendritic cell maturation and infiltration of antigen-specific T cells into the tumors. Thus, inhibition rates of primary and distant tumors reach >90%. In addition, BMS-202 NPs are able to attack spreading metastatic lung tumors and offer immune-memory protection to prevent tumor relapse. These results indicate that BMS-202 NPs possess effects similar to α-PD-L1 in the therapies of 4T1 tumors. Therefore, this work reveals the possibility of replacing the antibody used in immunotherapy for tumors with BMS-202 NPs.The ORCID identification number(s) for the author(s) of this article can be found under https://doi.

show abstract

Section: Methodsmentioning

confidence: 99%

Immune Checkpoint Blockade Mediated by a Small‐Molecule Nanoinhibitor Targeting the PD‐1/PD‐L1 Pathway Synergizes with Photodynamic Therapy to Elicit Antitumor Immunity and Antimetastatic Effects on Breast Cancer

Zhang

Zhu

et al. 2019

Small

136

114

View full text Add to dashboard Cite

show abstract

“…Nevertheless, given their importance in the early diagnosis, treatment, and monitoring of various diseases, assessment of tissue morphological structure, metabolism and physiological function, and pathological characteristics, much work is ongoing in this area . To date, PA imaging has been applied in the biological sensing of metal ions, pH, enzymes, temperature, hypoxia, reactive oxygen species (ROS), and reactive nitrogen species (RNS), as well as in the imaging of tumors, lymph nodes (LNs), vasculature, and brain tissue …”

Section: Introductionmentioning

confidence: 99%

Photoacoustic Imaging: Contrast Agents and Their Biomedical Applications

et al. 2018

View full text Add to dashboard Cite

Photoacoustic (PA) imaging as a fast‐developing imaging technique has great potential in biomedical and clinical applications. It is a noninvasive imaging modality that depends on the light‐absorption coefficient of the imaged tissue and the injected PA‐imaging contrast agents. Furthermore, PA imaging provides superb contrast, super spatial resolution, and high penetrability and sensitivity to tissue functional characteristics by detecting the acoustic wave to construct PA images. In recent years, a series of PA‐imaging contrast agents are developed to improve the PA‐imaging performance in biomedical applications. Here, recent progress of PA contrast agents and their biomedical applications are outlined. PA contrast agents are classified according to their components and function, and gold nanocrystals, gold‐nanocrystal assembly, transition‐metal chalcogenides/MXene‐based nanomaterials, carbon‐based nanomaterials, other inorganic imaging agents, small organic molecules, semiconducting polymer nanoparticles, and nonlinear PA‐imaging contrast agents are discussed. The applications of PA contrast agents as biosensors (in the sensing of metal ions, pH, enzymes, temperature, hypoxia, reactive oxygen species, and reactive nitrogen species) and in bioimaging (lymph nodes, vasculature, tumors, and brain tissue) are discussed in detail. Finally, an outlook on the future research and investigation of PA‐imaging contrast agents and their significance in biomedical research is presented.

show abstract

“…Local irradiation could then be used at the time of maximum accumulation at tumor sites. The combination of localized hyperthermia and chemotherapy led by CM-coated MPV inhibited tumor progression while maintaining low systemic toxicity (Zhai et al, 2018). RBM-decorated hollow mesoporous Prussian blue (PB) NPs were also employed for cooperative cancer therapy.…”

Section: Chemotherapymentioning

confidence: 99%

Cell Membrane-Camouflaged Nanocarriers for Cancer Diagnostic and Therapeutic

Li¹,

Liu²,

Sun³

et al. 2020

Front. Pharmacol.

View full text Add to dashboard Cite

Cell membrane (CM)-camouflaged nanocarriers (CMNPs) are the tools of a biomimetic strategy that has attracted significant attention. With a wide range of nanoparticle cores and CMs available, various creative CMNP designs have been studied for cancer diagnosis and therapy. The various functional CM molecules available allow CMNPs to demonstrate excellent properties such as prolonged circulation time, immune escape ability, reduced systemic toxicity, and homologous targeting ability when camouflaged with CMs derived from various types of natural cells including red and white blood cells, platelets, stem cells, and cancer cells. In this review, we summarize various CMNPs employed for cancer chemotherapy, immunotherapy, phototherapy, and in vivo imaging. We also predict future challenges and opportunities for fundamental and clinical studies.

show abstract

Traceable Bioinspired Nanoparticle for the Treatment of Metastatic Breast Cancer via NIR‐Trigged Intracellular Delivery of Methylene Blue and Cisplatin

Cited by 75 publications

References 66 publications

Immune Checkpoint Blockade Mediated by a Small‐Molecule Nanoinhibitor Targeting the PD‐1/PD‐L1 Pathway Synergizes with Photodynamic Therapy to Elicit Antitumor Immunity and Antimetastatic Effects on Breast Cancer

Immune Checkpoint Blockade Mediated by a Small‐Molecule Nanoinhibitor Targeting the PD‐1/PD‐L1 Pathway Synergizes with Photodynamic Therapy to Elicit Antitumor Immunity and Antimetastatic Effects on Breast Cancer

Photoacoustic Imaging: Contrast Agents and Their Biomedical Applications

Cell Membrane-Camouflaged Nanocarriers for Cancer Diagnostic and Therapeutic

Contact Info

Product

Resources

About